Organometallic Ligands

ZJ 43 is an advanced biochemical compound that serves as a precision-targeted reagent, specifically designed for cellular and molecular biology applications. Derived from synthetic organic chemistry techniques, it features a high degree of purity and specificity, allowing it to interact with cellular proteins without significant off-target effects. The compound primarily operates by modulating the activity of protein kinases, crucial enzymes in signaling pathways. ZJ 43 achieves this through a mechanism of competitive inhibition, where it binds to the active site of the kinase, thereby preventing substrate access and subsequent phosphorylation events. This selective inhibition is critical for dissecting signaling pathways in various experimental contexts. In terms of applications, ZJ 43 is employed extensively in research aimed at understanding the intricacies of signal transduction mechanisms and cellular responses to external stimuli. Its specificity makes it an invaluable tool in both basic and applied research, facilitating the development of targeted therapies for diseases where dysregulation of kinase activity is a contributing factor. Scientists leverage its properties to elucidate cellular processes at a molecular level, contributing to the advancement of precision medicine.

Please enquire for more information about JNK Inhibitor V including the price, delivery time and more detailed product information at the technical inquiry form on this page

Pd-85639 is a synthetic small molecule, which is a product of laboratory-derived chemical synthesis. Its structure mimics certain naturally occurring biomolecules that interact with cellular pathways pivotal in the regulation of cell growth and apoptosis. Specifically, Pd-85639 operates by inhibiting specific enzymes and signaling pathways, leading to the disruption of malignant cell proliferation and induction of programmed cell death. The primary applications of Pd-85639 involve research into its efficacy and mechanism of action in targeted cancer therapies. It is utilized in preclinical studies to better understand its potential role as a chemotherapeutic agent, particularly in cancers that exhibit resistance to conventional treatments. By interfering with key cellular processes, Pd-85639 offers insights into novel therapeutic strategies for oncology, making it a valuable tool in the development of new cancer treatment protocols.

Zoledronic acid monohydrate EP Impurity B is a chemical impurity often encountered in the synthesis and quality control of zoledronic acid. This impurity arises from synthetic pathways involved in the production of bisphosphonates, a class of compounds used for bone-related conditions. As an impurity, it does not have direct therapeutic action but plays a significant role in the characterization and purity assessment of pharmaceutical formulations. The mode of action, described indirectly, is related to its structural similarity to zoledronic acid, a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Understanding and controlling such impurities is crucial in pharmaceutical development to ensure drug efficacy and safety. Zoledronic acid monohydrate EP Impurity B is primarily used in analytical settings to provide standards for method validation and to support regulatory compliance in the manufacture of zoledronic acid. Its detailed study aids in understanding the chemical behavior of bisphosphonates and is valuable in the advancement of medicinal chemistry, particularly concerning bone diseases such as osteoporosis and certain cancers involving bone metastasis.

Potent inhibitor of c-Met catalytic activity. Selective over other tyrosine and serine-threonine kinases (600-fold selectivity). Ability to block constitutive or HGF-stimulated phosphorylation of c-Met demonstrated in vitro. JNJ 38877605 reduces radiation-induced invasion, apoptosis and proliferation of cancer cells in vitro.

S29434 is a synthetic compound that functions as a selective adenosine A2A receptor antagonist. Originating from chemical synthesis, this product is designed to bind selectively to the A2A subtype of adenosine receptors, which are G protein-coupled receptors widely expressed in the central nervous system and peripheral tissues. The mode of action for S29434 involves antagonizing the interaction between adenosine and its A2A receptors. By blocking these receptors, S29434 can modulate neurotransmitter release, particularly dopamine, and influence various physiological processes such as inflammation, immune response, and neuronal activity. In scientific research and experimental applications, S29434 is utilized to explore the role of A2A receptors in neurodegenerative disorders like Parkinson's disease, as well as potential therapeutic effects in cardiovascular diseases and certain types of cancer. Its ability to provide insights into the adenosine signaling pathway makes it a valuable tool for laboratories investigating molecular and cellular mechanisms.

AZD9567 is a selective glucocorticoid receptor modulator (SGRM), which is a synthetic pharmaceutical compound. Its source is rooted in medicinal chemistry efforts to design ligands that selectively interact with glucocorticoid receptors. The mode of action of AZD9567 involves binding to glucocorticoid receptors with high specificity, modulating their activity to trigger anti-inflammatory and immunomodulatory responses while minimizing common side effects associated with traditional glucocorticoids. The applications of AZD9567 are primarily in the treatment of inflammatory and autoimmune conditions, where modulation of the immune response is desired. It is under investigation for potential uses in diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease, among others. By acting as a selective modulator, AZD9567 aims to provide the therapeutic benefits of glucocorticoids with a reduced risk of adverse effects, such as osteoporosis and metabolic disturbances, making it a subject of interest in ongoing research and clinical trials.

A non-metabolizable allolactose analogue, widely used in molecular biology for overexpression of recombinant proteins from inducible systems under the control of lac promoter. IPTG binds to the LacI repressor and causes its release from the lac operator, allowing gene expression to take place. Present in vectors of pGEX, pGEM-T, pET, pRSET, pMAL class and others.

Orally available and central nervous system-penetrant inhibitor of GlyT1 glycine transporter SLC6A9. PF 03463275 was shown to enhance neuroplasticity and cognitive remediation in schizophrenia patients. In animal studies, PF 03463275 also influenced retina as changes in electroretinogram were detected in albino rats.

Please enquire for more information about GR79236 including the price, delivery time and more detailed product information at the technical inquiry form on this page

TL4-12 is a gene editing tool, which is a synthetic construct engineered through advanced biotechnological techniques. It operates via CRISPR-Cas9 technology, enabling the precise targeting and modification of specific genomic sequences in living cells. The Cas9 enzyme acts as molecular scissors, guided by a custom RNA sequence within TL4-12 to a unique DNA target location. This tool is utilized in a range of applications, including genomic research, functional gene studies, and therapeutic genome editing. TL4-12 allows scientists to investigate gene function, understand genetic disorders, and potentially correct pathogenic mutations. With its high specificity and efficiency, it contributes significantly to advancements in genetic therapy and molecular biology research, providing a powerful resource in the ongoing exploration of gene function and regulation.

SKF83822 hydrobromide is a selective dopamine receptor agonist, which is synthetically derived with a specific affinity for dopamine D1 receptors. Its mode of action involves the targeting and activation of these receptors, offering a unique tool for research into dopamine-related signaling pathways. Due to its specificity, SKF83822 hydrobromide is utilized extensively in neuroscientific research to investigate the roles of D1 receptors in various physiological and pathological contexts. The compound finds substantial application in the study of neurological disorders such as Parkinson's disease and schizophrenia, where dopamine signaling is critically implicated. Researchers employ SKF83822 hydrobromide to understand the complexities of receptor activity and downstream effects, contributing to the broader comprehension of dopamine function and signaling. As a research tool, this compound provides valuable insights into pharmacological mechanisms and potential therapeutic targets, facilitating advancements in neuropharmacology.

N-Methoxysuccinyl-Ala-Ala-Pro-Met p-nitroanilide is a synthetic chromogenic substrate, which is typically utilized in biochemical assays to assess protease activity, particularly that of elastase-like enzymes. The product is derived from chemical synthesis in the laboratory, featuring a specific peptide sequence conjugated to the p-nitroanilide group. This substrate functions by being hydrolyzed by targeted proteases, releasing p-nitroaniline, which can be quantitatively measured due to its distinct absorbance at 405 nm. This mechanism allows researchers to determine protease activity by monitoring changes in absorbance over time. Applications of N-Methoxysuccinyl-Ala-Ala-Pro-Met p-nitroanilide are predominantly found in enzymology research, where it serves as a crucial tool to dissect protease kinetics, inhibitor screening, and other functional studies related to protease activity in physiological and pathological contexts. The ability to quantify enzyme activity using this chromogenic substrate aids in advancing our understanding of complex biological processes and the development of therapeutic strategies.

MD2-TLR4-IN-1 is a synthetic bioactive compound, which is a selective inhibitor predominantly targeting the TLR4/MD2 signaling complex. It is sourced from advanced chemical synthesis techniques focusing on the modulation of immune receptors. The mode of action of MD2-TLR4-IN-1 involves binding to the MD2-TLR4 complex, thereby inhibiting its activation and subsequent downstream signaling pathways. This results in the suppression of pro-inflammatory cytokine production. The primary applications of MD2-TLR4-IN-1 are in the fields of immunology and inflammation research. It is utilized in experimental settings to investigate the role of TLR4 in immune response and to explore potential therapeutic avenues for conditions characterized by excessive inflammation, such as sepsis, rheumatoid arthritis, and other inflammatory or autoimmune diseases. The use of MD2-TLR4-IN-1 provides valuable insights into TLR4-mediated signaling cascades and assists in the validation of targets for novel anti-inflammatory drug development.

JNJ-40418677 is a small-molecule pharmaceutical compound that functions as a highly selective phosphodiesterase 10A (PDE10A) inhibitor. It is developed from synthetic chemical sources and is designed to modulate intracellular signaling pathways by targeting the PDE10A enzyme. The mode of action involves inhibition of PDE10A, which is predominantly expressed in the striatum-a brain region linked to motor control and cognitive functions. By inhibiting PDE10A, JNJ-40418677 increases the levels of cyclic nucleotides (cAMP and cGMP) within neurons, which can enhance dopaminergic and glutamatergic signaling pathways. This compound is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders, such as schizophrenia and Huntington's disease. The augmentation of intracellular signaling processes may ameliorate symptoms associated with these conditions by improving neural communication and synaptic plasticity. Current studies focus on the efficacy, safety, and pharmacokinetic profiles of JNJ-40418677 to determine its viability as a treatment option and to understand its long-term impact on brain function and behavior. The targeted approach of this compound could lead to advances in managing complex neurodegenerative and psychiatric diseases.

N-[(E,2S,3R)-1,3-Dihydroxyhexadec-4-en-2-yl]hexadecanamide is a bioactive lipid molecule, which is a derivative of sphingolipids, commonly found in higher eukaryotes. Sphingolipids are crucial components of cell membranes and play significant roles in cellular signaling pathways. This specific compound exhibits a unique configuration with both hydroxyl and amide functionalities that contribute to its interaction with biological membranes and proteins. The source of this lipid involves complex biosynthetic pathways where ceramides serve as precursors, undergoing enzymatic transformations. The compound interacts with and modulates various signaling cascades, particularly those involved in cell growth, differentiation, and programmed cell death (apoptosis). Its mode of action typically encompasses the regulation of protein kinases and phosphatases, affecting downstream signaling components. N-[(E,2S,3R)-1,3-Dihydroxyhexadec-4-en-2-yl]hexadecanamide finds its applications in research related to cellular processes, such as in studies of cancer biology, neurodegenerative diseases, and metabolic disorders. It provides insight into the role of lipid signaling in disease mechanisms and potential therapeutic innovations. These attributes make it a subject of interest in both basic and applied scientific research.

Antagonises CXCR4 selectively by blocking Ca2+ release (IC50 from 0.02 to 0.13 µM). Studied in SDF-1/CFXCR4-dependent functions in HIV, rheumatoid arthritis and breast cancer metastasis. Enhances mobilization of hematopoietic stem cells (HSCs) and Hematopoietic progenitor cells (HPCs) for re-populating hematopoietic progenitors for transplants in vivo and attenuates cocaine-induced locomotor activation.

Inactive enantiomer of the inhibitor of myosin II-ATPase

MG 132 is a modified tripeptide that acts as proteasomal inhibitor. In 2006, MG 132 has been experimentally tested in in vitro cell-based and in vivo models for to assess its use in the medical treatment of Parkinson's disease.

7-((Benzo[D]thiazol-2-ylamino)(4-(difluoromethoxy)phenyl)methyl)quinolin-8-ol is a synthetic investigational compound, which is typically synthesized in a laboratory setting through a series of chemical reactions involving quinoline derivatives and other complex organic molecules. This compound is designed to target and inhibit specific molecular pathways involved in cancer cell proliferation and survival. Its mode of action is believed to involve the disruption of signaling pathways critical to tumor growth, potentially through interaction with specific kinases or receptor sites on the cancer cells. The applications of this compound primarily lie within the field of oncology research, where it is being explored for its efficacy as a therapeutic agent against various types of cancer. Its potential to induce apoptosis or inhibit proliferation of cancer cells makes it a candidate for further study in preclinical and clinical settings. Research efforts are focused on elucidating its full mechanism of action, determining its pharmacokinetics, and evaluating its safety profile in biological systems. Investigations into its synergistic effects with existing cancer therapies are also of significant interest in optimizing its potential use as part of combination treatment regimens.